Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Inclusion Body Myositis (IBM) - Overview
Inclusion Body Myositis (IBM) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Inclusion Body Myositis (IBM) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
Inclusion Body Myositis (IBM) - Drug Profiles
Inclusion Body Myositis (IBM) - Dormant Projects
Inclusion Body Myositis (IBM) - Discontinued Products
Inclusion Body Myositis (IBM) - Product Development Milestones
Featured News & Press Releases
Nov 05, 2021: Abcuro to present late-breaking abstract at American College of Rheumatology Convergence 2021 of ABC008 inclusion body myositis phase 1 data demonstrating proof of mechanism for selective depletion of highly cytotoxic T cells
Oct 06, 2021: Abcuro to present trial in progress poster on a phase 1 clinical trial of ABC008 demonstrating targeted depletion of large granular lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress
Jun 30, 2021: Abcuro and Imagib share initial results of study using novel technology for imaging T cell infiltration of skeletal muscle in patients with inclusion body myositis
Apr 01, 2021: Nobel Pharma announces notice of desigtion of orphan drug
Aug 22, 2017: Ultragenyx Announces Top-Line Results from Phase 3 Study of Ace-ER in GNE Myopathy
Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union
Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy
Oct 02, 2015: Ultragenyx Announces Aceneuramic Acid Prolonged Release Marketing Authorization Application Filed and Accepted for Review by European Medicines Agency
May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
Jan 12, 2015: Ultragenyx Announces Intent to File for Conditiol Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at Intertiol Congress of the World Muscle Society
Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress
Jul 03, 2013: Ultragenyx Announces a Positive Sigl in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Inclusion Body Myositis (IBM), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Inclusion Body Myositis (IBM), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Inclusion Body Myositis (IBM) - Pipeline by AAVogen Inc, 2022
Inclusion Body Myositis (IBM) - Pipeline by Abata Therapeutics, 2022
Inclusion Body Myositis (IBM) - Pipeline by Abcuro Inc, 2022
Inclusion Body Myositis (IBM) - Pipeline by Alzheon Inc, 2022
Inclusion Body Myositis (IBM) - Pipeline by Cleave Therapeutics Inc, 2022
Inclusion Body Myositis (IBM) - Pipeline by Leadiant Biosciences Inc, 2022
Inclusion Body Myositis (IBM) - Pipeline by Milo Biotechnology LLC, 2022
Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co Ltd, 2022
Inclusion Body Myositis (IBM) - Pipeline by PhaseBio Pharmaceuticals Inc, 2022
Inclusion Body Myositis (IBM) - Pipeline by Vandria SA, 2022
Inclusion Body Myositis (IBM) - Dormant Projects, 2022
Inclusion Body Myositis (IBM) - Discontinued Products, 2022